Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03743038 · ClinicalTrials.gov registry record · Phase 1
A Study Comparing Two Topicals in the Treatment of Acne Vulgaris
A Phase 1 study, sponsored by Vyne Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03743038 is a Phase 1 study that has completed, run by Vyne Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT03743038, a Phase 1 study, has completed, sponsored by Vyne Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
A Randomized, Evaluator-Blinded, Bilateral Comparison Study to Evaluate the Safety and Efficacy of Two Topicals in the Treatment of Subjects With Acne Vulgaris (Study FX2018-23).
Interventions
- DRUG FMX101 vehicle
- OTHER Hydro-alcohol solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-11-20 |
| Est. Completion | 2019-02-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03743038
The ClinicalTrials.gov registry entry for NCT03743038 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vyne Therapeutics, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FMX101 vehicle is the first listed.
NCT03743038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03743038 about?
NCT03743038 is a clinical study titled "A Study Comparing Two Topicals in the Treatment of Acne Vulgaris". A Randomized, Evaluator-Blinded, Bilateral Comparison Study to Evaluate the Safety and Efficacy of Two Topicals in the Treatment of Subjects With Acne Vulgaris (Study FX2018-23).
What is the current status of trial NCT03743038?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-11-20. Estimated completion is 2019-02-11.
What interventions are being tested in trial NCT03743038?
The interventions under investigation include: FMX101 vehicle (DRUG), Hydro-alcohol solution (OTHER).
Who is sponsoring clinical trial NCT03743038?
This trial is sponsored by Vyne Therapeutics, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.